Fundraising FoxACVC Partners — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Amaryllis Tx develops tissue-targeted drug delivery by mapping tissue-specific glycan signatures and designing peptides that recognize them, using in silico and in vivo screening.
AI & Machine LearningBiotechDeep TechCambridge, US
Jeongseuk Kang(Executive Officer, Director)
BoardEmmanouil Karagiannis(Director)
Co-investorsThe Ventures Co
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
BiotechDeep TechSan Carlos, US
Matthew Hill(Executive Officer, Director)in
BoardPeter Zhou(Director)inCain McClary(Director)inJonathan Sheena(Director)in
Co-investorsAndreessen HorowitzIn-Q-TelKdT VenturesRaptor GroupTriatomic CapitalAME Cloud Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.